Real-Life Outcomes of 8 Weeks Regimen of Sofosbuvir and Ledipasvir without Ribavirin, in Non-Cirrhotic Treatment-Naïve Hepatitis C Genotype 1 Patients with less than 6 Million IU/ML Viral Load

Qureshi, Kamran; Andres, Jennifer; Regester, John; Lott, Stephen; Halladay, J.; Peleckis, C.; Urick, Paul

doi:10.1016/s0168-8278(16)01532-4

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also supports the real‐world effectiveness study by Ioannou and colleagues for the VA cooperative and supports the VA treatment guidelines and the English National Health Service guidance on shortening duration of treatment in noncirrhotic treatment‐naïve patients with HCV RNA <6 million IU/mL . The generalisability of the clinical data from ION‐3 has also been demonstrated by multiple other, real‐world studies comparing 8 vs 12 weeks of LDV/SOF multiple geographies and patient care settings including patients with HIV disease …”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Curry

Tapper

Bacon

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

“…Last, the English National Health Service guidance recommends 8 weeks of LDV/SOF for noncirrhotic treatment‐naïve genotype 1 HCV infected patients regardless of HCV viral load . Several heterogeneous real‐world cohort studies have reported excellent SVR rates for patients treated for 8 weeks with LDV/SOF±ribavirin …”

Section: Introductionmentioning

confidence: 99%

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Curry

Tapper

Bacon

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Hepatitis C: efficacy and safety in real life

Flisiak

Pogorzelska

Flisiak-Jackiewicz

2017

Liver International

View full text Add to dashboard Cite

Interferon-free combinations were registered in 2014 and 2015 for the treatment of chronic HCV infection. As a result, real-world experience has been gathered in the last year and this paper presents data available in September 2016. Real-world studies on the efficacy of the ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen showed a sustained virologic response (SVR) rate of between 91% and 98%. The SVR rate in the 13858 patients included in this paper was 94%, and 92% in the 3506 patients with cirrhosis. In a number of recently published real-world studies evaluating ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±RBV, the SVR rate was between 92% and 100%. The SVR rate of the 4260 patients included in the studies in this paper was 97% and the rate was the same in the 1647 patients with cirrhosis. Recently, data evaluating SOF/simeprevir±RBV showed an SVR rate >90%, while in combination with daclatasvir this rate reached approximately 95%. The safety data available for LDV/SOF±RBV and OBV/PTV/r±DSV±RBV show that discontinuation due to adverse events was necessary in no more than 3% of patients and the frequency of serious adverse events was between 0 and 11%, in particular in real-world studies. Because of the similar efficacy and safety, real-world data support the use of either the LDV/SOF±RBV or OBV/PTV/r±DSV±RBV regimen in patients with genotypes 1 or 4. There is still not enough real-world data in patients with genotype 3 and other genotypes.

show abstract

Real-Life Outcomes of 8 Weeks Regimen of Sofosbuvir and Ledipasvir without Ribavirin, in Non-Cirrhotic Treatment-Naïve Hepatitis C Genotype 1 Patients with less than 6 Million IU/ML Viral Load

Cited by 2 publications

References 0 publications

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

Hepatitis C: efficacy and safety in real life

Contact Info

Product

Resources

About